GenSci143 / GeneScience - LARVOL DELTA

GenSci143, a novel B7-H3×PSMA bispecific and potential best-in-class ADC, for the treatment of metastatic castration-resistant prostate cancer (AACR 2025) - "In vivo anti-tumor activity of GenSci143 was assessed in CDX models of PCa and compared to that of the DS-7300 and ARX517 analogs. B7-H3 and PSMA were highly co-expressed in PCa tissues (N=102), lending strong support to our dual-targeting therapeutic approach for mCRPC. These results suggest that GenSci143 has the potential to become an effective therapeutic option for mCRPC patients and support its further evaluation in IND-enabling studies."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD276